The Vioxx withdrawal: latest in the COX-2 controversies.
Mandell
Brian F
BF
D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D013450:Sulfones / Q000009:adverse effects*; D014481:United States
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib